Gastrointestinal side effects are by far the most prevalent during early treatment: Nausea Very common (may affect more than 1 in 10 people), typically peaking during the first week and often improving over two to four weeks [1] [2] Vomiting Common (may affect up to 1 in 10 people), usually occurring alongside nausea [1] [2] Diarrhoea Common, may persist for several weeks Constipation Common, sometimes alternating with diarrhoea Abdominal pain or discomfort Common, ranging from mild cramping to more pronounced discomfort Dyspepsia (indigestion) Common Eructation (belching) Common Reduced appetite A therapeutic effect that may feel uncomfortable initially, affecting eating patterns These symptoms arise because semaglutide mimics the natural GLP-1 hormone, which slows gastric emptying and increases satiety

Given that more than half of total knee and hip arthroplasty patients meet criteria for obesity or morbid obesity, weight loss strategies, particularly pharmacologic approaches like GLP-1 receptor agonists, are becoming increasingly relevant in optimizing surgical outcomes and mitigating complications
Mestria S et al
GLP-1 receptor agonists are effective for treating obesity and diabetes, but the high cost and high rates of gastrointestinal adverse effects can lead to treatment cessation and subsequent weight regain, the researchers explained
Effects of dietary L-carnitine on puberty indices in the young breeder rooster [PMID: 33898844] Laboratory literature summary: Effects of dietary L-carnitine on puberty indices in the young breeder rooster